Instituto Alexander Fleming

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Cervical cancer1 trial
• Head and neck cancer1 trial
• Liver and biliary tract cancer1 trial
• Ovarian cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 32 trials
• Phase 1/21 trial

Status

• Active, not recruiting1 trial
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Amgen3 trials

Running trials

• Active, not recruiting

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· Phase 3· Amgen· Source

• Recruiting

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· Phase 3· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer1 recruiting

Closed trials

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Amgen· Source